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Machine perfusion systems have been rapidly arising as an alternative to cold storage for organ 
preservation. Various pre-clinical and clinical trials have established the use of machine 
perfusion in extending preservation time and resuscitating organs procured from extended 
criteria donors. However, this technique has not been thoroughly explored for use with 
vascularized composite allografts (VCA). The purpose of this thesis was to incorporate 
subnormothermic (21°) machine perfusion into a novel multi-parametric bioreactor system for 
preserving abdominal wall grafts in a murine model. The bioreactor is a closed-environment 
chamber that provides electrical stimulation of the muscular component of the graft to improve 
function and prevent atrophy. It also allows for real-time monitoring of perfusate metabolites via 
in-line sensors to determine graft viability. Rat abdominal grafts were perfused for 12 hours with 
heparinized saline (HSa) or a modified histidine-tryptophan-ketoglutarate (HTK) solution. These 
grafts were compared to cold-stored and room-temperature stored grafts. Histopathological 
analysis during preliminary studies revealed that machine perfusion resulted in greater 
deterioration of grafts when compared to other storage techniques. It was concluded that, 
although the bioreactor system was successful in accessing graft vasculature and acquiring data 
from in-line sensors, the HSa and HTK solutions were not sufficient for graft preservation. 
Future experiments are necessary to determine additions to the perfusate for optimal graft 
preservation. Further work is needed to establish parameters of different metabolites to 
determine graft viability throughout the perfusion time. Electrical stimulation protocols must also 
be optimized. Efforts are on-going to finalize the bioreactor design and to develop a system that 
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Vascularized composite allotransplantation (VCA-Tx) is a procedure that involves transplanting 
vascularized composite allografts (VCA) as a functional unit. It can correct defects that cannot 
be reconstructed with autologous tissues. Examples of VCAs include facial and extremity 
transplants. VCA-Tx has the potential to treat thousands of individuals world-wide. In the United 
States alone, there are over two million amputees, with trauma accounting for the majority of 
these cases. VCA-Tx is a life-changing procedure that can improve quality of life by restoring 
function and aesthetics. However, a major barrier to the routine implementation of this surgical 
procedure is the preservation of allografts prior to transplantation. The gold standard for organ 
and VCA preservation is cold storage. However, VCAs are especially challenging to preserve 
with this method because of their composite nature. Each tissue type has different ischemic 
tolerance, with muscle being the most vulnerable to cold ischemic insult. Most grafts must be 
transplanted within four to ten hours of harvest in order to maintain viability of the muscle 
component. Machine perfusion systems with a wide range of variables, including temperature, 
perfusate, and flow regimens, have shown promise in clinical settings of solid organ 
preservation. Evidence from many animal and human studies suggest that machine perfusion can 
successfully preserve VCAs. The purpose of this project is to investigate the feasibility of 
extending VCA preservation time with a bioreactor system that can simulate physiologic 
conditions. The following narrative will explore the origins of machine perfusion as a method of 
organ preservation and the expanding efforts to establish this technology in the field of VCA-Tx. 





by the design and realization of a customized bioreactor chamber with electrical stimulation and 





2. Overview of Literature 
 
2.1 Solid Organ Ex-Vivo Machine Perfusion 
 
2.1.1 Origins of research in ex-vivo solid organ machine perfusion  
 
The idea of extracorporeal circulation can be traced back to the 19th century. The belief, as 
expressed by Julien Jean Le Gallois, was that any portion of the body could be maintained 
indefinitely as long as the function of the heart and lungs could be replaced [1]. This set into 
motion research efforts to determine the plausibility of his statement. Early experiments in the 
1800s involved injection of blood, oxygenated by physical agitation, into dismembered limbs 
[1]. As ideas progressed and developed, primitive perfusion machines were constructed that 
could establish and control blood pressure and flow rates. Alexander Schmidt and Carl Ludwig 
were likely the first to incorporate a method of blood oxygenation to their perfusion circuits [2]. 
The goal of these perfusion experiments shifted from maintenance of the organ to understanding 
their physiological action after removal from the body. By doing so, researchers were able to 
solve many physiological problems in observing the organ or tissue outside of the body [2]. As 
more researchers became involved in the endeavor, closed circulation systems were developed 
and improved upon. An apparatus by Richards and Drinker allowed for the continuous 
oxygenation and perfusion of blood through isolated mammalian organs. Whereas previous 
iterations of such machines required repeated cessations of perfusion in order to oxygenate 
venous outflow, this apparatus made continuous perfusion possible [3]. They accomplished this 
by employing a dual pump system that simultaneously pumped blood through the organ under 





limitation, in that they had to be manually powered. To bypass this challenge, electrically 
powered pumps began to appear in the literature, with the first electric rotary pump being 
described in 1913 [1]. As the foundations were laid for artificial circulation, physicians began to 
work on modifying the technology for use during cardiovascular procedures in humans. A 
limiting factor during correction of cardiac defects is the presence of blood in the surgical field, 
which makes it difficult for surgeons to clearly visualize defects and subsequently repair them. 
Through the combined efforts of scientists and physicians, perfusion systems were outfitted to 
bypass the heart and lungs, which served to render the heart dry for optimal surgical conditions. 
These efforts ultimately led to the development of the heart-lung machine as we know it today, 
one of the first instances of its use in a clinical setting being in 1951 [4]. This machine set the 
precedent for future systems that could safely and effectively perfuse tissues in a clinical setting. 
 
2.1.2 Ex-vivo machine perfusion in solid organ transplantation 
 
As organ transplantation became more and more established in the clinical setting in the 1960s, 
there was a need to revisit the original concept of Le Gallois: to preserve an organ once it had 
been removed from the body. Improvements in surgical technique resulted in transplant success 
rates that increased every year; as of 2016, one-year graft survival rates for kidney transplants are 
more than 90% [5]. However, one of the primary challenges of transplantation remains organ 
preservation. The first extracorporeal perfusion circuits required large amounts of autologous 
blood as the perfusate, which in many cases, was not sufficient from the animal subject itself. 
This often led to the supplementation with blood of other species, which understandably caused 
great harm to the perfused organ, and would not be feasible in a clinical setting [2]. In the late 





of canine kidneys, with considerable success in transplantation [6]. However, the use of plasma-
derived products presented the risk of spreading disease, and so there arose a need for a synthetic 
perfusate. Collins revolutionized organ preservation by developing a preservation solution that 
mimicked the intracellular environment of the kidney [6]. This perfusate, known as Collins’ 
solution, led to the development of simple cold storage. This method involved flushing the blood 
from the organ with Collins’ solution and storing at 4°C. Cold storage allowed renal preservation 
for 24-36 hours, and quickly surpassed the effectiveness of machine perfusion systems, which 
were greatly stunted by the technology available at the time [7]. The success and simplicity of 
this preservation method edged out burgeoning efforts to develop continuous perfusion machines 
[8]. Cold storage was more cost-effective and less technically challenging than machine 
perfusion. It became the most recognized preservation and storage technique, and persists to this 
day [6,7]. Despite the success of cold storage in preserving a variety of organs, evidence began 
to support the theory that injuries acquired during the preservation period could predispose the 
organ to rejection and result in transplant failure. A retrospective study of 215 liver transplants 
recipients in 1990 revealed a relationship between cold-ischemia time and postoperative primary 
graft function [9]. Under hypoxic conditions, cells switch to anaerobic metabolism, leading to a 
host of detrimental processes. Hydrogen ions begin to accumulate, decreasing cell pH and 
producing a large influx of sodium ions. Ischemia depletes cellular ATP, setting off a positive 
feedback loop that further impairs ATP production. These pathways, and many more, lead to 
disrupted cellular structures and eventual cell death [10]. Prompt reperfusion and oxygen 
delivery are essential to reverse tissue damage. However, organs subjected to periods of ischemia 
followed by oxygenated reperfusion often sustain ischemic-reperfusion injuries (IRI), a 





encompasses a variety of complex and multi-faceted physio-pathological molecular cascades 
responsible for graft injury, including generation of reactive oxygen species (ROS), calcium 
overload, endothelial dysfunction, and enhanced inflammatory responses, among others [7,10]. 
The effects of reperfusion injury are so dramatic that cell death can continue for up to three days 
following the reperfusion phase [10]. It was evident that organ storage and preservation 
strategies had to be modified to mitigate the effects of hypoxia and IRI. Machine perfusion holds 
the potential to improve preservation by mimicking physiological conditions, and so there is 
much research into improving aspects of ex-vivo circulation, including the perfusate 
composition, the pump mechanism, and temperature. There were extensive efforts into creating a 
synthetic perfusate that could replace the functionality of blood and eliminate the challenges that 
come with it. Many solutions have emerged to suit the unique needs of different organs; these 
will be discussed in more detail in a later section. To mimic the action of the heart, double-acting 
pumps were introduced. These pumps establish a pulsatile flow that varies vessel diameter and 
movement of perfusate through them, more closely mimicking the natural flow of blood in the 
body [1]. Machine perfusion can support metabolism during preservation by providing oxygen 
and nutrients, which can reduce ischemia time. Viability testing has also evolved over the years 
and has proven to be an advantage over cold storage as it allows organs to be assessed for 
damage and to predict graft function prior to transplantation. For example, markers of 
dysfunction, such as aspartate aminotransferase (AST) for livers and glutathione-S-transferase 
for kidneys, can be evaluated and be used as predictors of function [11,12]. Temperature of 
perfusion is also an important factor in the support of an organ. At normothermic temperatures, 
organs experience more physiologic conditions, and it follows that preservation would be more 





injury and improves post-transplantation function in livers [12]. However, there is also evidence 
that subnormothermic perfusion can be similarly effective in preservation [13]. Overall, machine 
perfusion may hold the key to true organ banking practices, and there is much research going on 
to reach this ultimate goal.  
    
2.1.3 Animal models of organ transplantation with machine perfusion 
 
There have been countless animal models used to evaluate machine perfusion for organ 
transplantation. Canine, porcine, and murine models are among the most common. For brevity, 
only a few notable kidney, liver, and heart transplant studies will be discussed in this section.  
 
Kidney transplantation. Several studies have shown the merit of machine perfusion over simple 
cold storage. Although kidney grafts fare particularly well with cold storage, machine perfusion 
can improve function in grafts obtained from donors after circulatory death (DCD) which 
undergo periods of warm ischemia. This is important because warm ischemia can only be 
tolerated for short amounts of time before irreversible damage occurs. A porcine study was able 
to salvage DCD kidneys that suffered over two hours of warm ischemia with machine perfusion. 
This could increase the donor pool and be more cost-effective than cold storage in the long term 
[14]. A rat kidney model evaluated the use of rewarming via oxygenated perfusion after 24 hours 
of cold storage at 4°C. Kidney viability was monitored by measuring injury biomarkers and renal 
function parameters in the perfusate and urine [15]. There were lower levels of injury markers 
(e.g. AST and lactate dehydrogenase) and higher parameters of function (e.g. sodium re-
absorption and urine production) in rewarmed kidneys versus cold stored kidneys. Histology also 





murine study mimicked the procurement of DCD kidneys and compared cold storage and 
normothermic and hypothermic perfusion with oxygenated blood prior to transplantation [16]. 
They found that hypothermic perfusion was superior to normothermic perfusion in that it 
preserved more renal structures and caused less release of ROS. However, it was evident that 
both normo- and hypothermic perfusion protocols were superior to cold storage alone [16]. 
Numerous porcine models have established the benefit of machine perfusion over cold storage in 
DCD models. Most studies subjected kidney grafts to machine perfusion after variable times of 
warm and cold ischemia, after which reperfusion was simulated by perfusing the organ with 
normothermic blood on an isolated perfusion system. Despite variability in perfusate, flow rate, 
temperature and pressure settings among these studies, all of them saw improved graft function 
in machine perfusion groups when compared to cold storage [17–23]. Non-transplant models 
assessed viability by measuring different biomarkers of injury and parameters of function. A 
renal autotransplantation model showed that hypothermic machine perfusion kidneys, when 
compared to cold storage kidneys, had less ROS production upon reperfusion, less proximal 
tubule damage (as assessed by brush border enzymes and lysosomal enzymes), and lower serum 
creatine levels [21]. Two studies utilizing a canine autotransplantation model assessed the effect 
of machine perfusion in restoring kidneys subjected to varying warm ischemia times. One study 
exposed kidneys to two hours of warm ischemia. Kidneys were either replanted immediately, 
hypothermically perfused for 18 hours, or subnormothermically (32°C) perfused for 18 hours. 
Kidneys perfused at 32°C showed life-sustaining function, with serum creatinine levels 
normalizing on post-operative day 9. However, the other two groups did not seem to recover 
from ischemic damage and were anuric posttransplant with resulting uremia [24]. The other 





30 minutes [25]. Both studies used acellular oxygenated solutions, which establishes synthetic 
perfusates as feasible options to recover renal function following warm ischemia. These studies 
involving DCD models demonstrate that kidneys can be pre-conditioned prior to transplant with 
machine perfusion to improve rates of graft function, particularly in marginal donors. 
 
Liver transplantation. Applying machine perfusion to livers is challenging because it receives 
blood through two vessels: the portal vein and hepatic artery. However, there have been 
numerous studies and advances made in the preservation of livers, especially for extended 
criteria donors. A murine study found that machine perfusion of DCD livers at varying 
temperatures (4°C, 12ºC, 21ºC) provided superior liver function over cold storage and was 
comparable to non-DCD controls [13]. However, these grafts were perfused with a synthetic, 
acellular solution, and it was clear that an oxygen carrier was necessary to meet hepatocyte 
oxygen demand during higher temperatures of perfusion, since metabolic activity is increased. 
Another murine study using a perfusate with red blood cell concentrate as the oxygen carrier 
found that normothermic perfusion reduced bile duct injury and improved biliary epithelial 
function when compared to cold storage in DCD livers. Concentrations of biliary bicarbonate, 
reflecting biliary epithelial function, were significantly higher in machine preserved livers and 
comparable to non-DCD livers. A similar trend was found with biomarkers of bile duct injury 
[26]. Multiple porcine studies have also been carried out throughout the years. Porcine liver 
models more reliably predict human outcomes. Two studies observed the effect of one-hour 
warm ischemia time. Upon reperfusion to simulate transplantation, cold stored livers were non-
viable with no bile production or glucose uptake and considerable necrosis. In contrast, machine 





indictor of liver cell damage), increased ATP levels, and increased blood flow [27–30]. Even 
when warm ischemia is not a factor in liver procurement, machine preservation saw decreased 
ALT, increased bile production, and decreased reperfusion injury when compared to cold storage 
[27]. A severe complication unique to liver transplants is the occurrence of non-anastomotic 
biliary strictures (NAS), also termed ischemic-type biliary lesions. NAS can occur in as many as 
30-50% of DCD liver transplants. Studies have shown that machine perfusion could have 
protective effects on the biliary tree and prevent NAS, which could expand the donor pool [31]. 
Animal models and data from discarded human livers provide some evidence that machine 
perfusion reduces bile duct injury, and restores regenerative capabilities of biliary epithelium 
[31]. A murine study sought to understand the mechanisms of recovery in order to allow more 
rational optimization of perfusion systems [32]. Fresh and DCD livers were subjected to 
normothermic machine perfusion for six hours and subsequently transplanted. Metabolic 
analyses of major pathways, including amino acid metabolism, glucose metabolism, oxygen 
uptake, and electron transport, were obtained. Results showed that livers were stable over the six 
hour machine perfusion period and warm ischemic livers recovered to a transplantable state after 
two hours [32]. These studies, and many more throughout the decade [30], provide evidence that 
supports the ability of oxygenated machine perfusion to restore livers that have undergone warm 
ischemia (i.e. DCD livers).  
 
Heart transplantation. Cardiac transplantation faces the same challenges as other organ 
transplantations, namely, donor shortage. Extended criteria donors have the potential to increase 
the donor pool, but organs from these sources are often not eligible for transplant due to high risk 





perfusion can offer myocardial protection during the preservation phase [33–39]. When 
compared with cold storage, machine perfusion, regardless of temperature, produced hearts with 
decreased lactate levels, increased energetic metabolism, and increased contractility [34,35,37]. 
A study evaluated canine hearts after four hours of cold storage versus hypothermic machine 
perfusion, after which they were connected to a non-working heart Langendorff system. The 
Langendorff system allows monitoring of isolated hearts; many parameters can be analyzed in 
real time, including pressure, biopotentials, and heart rate [40]. They found that the cold stored 
hearts had intramyocardial acidosis and significant ATP depletion. In contrast, machine perfused 
hearts had less oxidative damage and cell apoptosis. Machine perfused hearts also had increased 
systolic and diastolic function. In another branch of this study, machine perfusion was able to 
reanimate canine hearts that had suffered one hour of warm ischemia. These hearts demonstrated 
full functional recovery upon connection to the Langendorff system, whereas cold stored hearts 
showed no systolic function [34]. The effect of machine perfusion on ideal donor hearts, i.e. with 
little to no warm ischemic time, was also evaluated. It was found that, in comparison to cold 
storage, machine perfused hearts had improved hemodynamics, decreased myocardial acidosis, 
increased energy storage and improved endothelial function [34]. Two studies transplanted 
preserved donor hearts in canines and pigs and were able to demonstrate superior function in 
machine perfused hearts [38,39]. One study preserved hearts for 14 hours with cold storage or 
retrograde perfusion through the coronary sinus. The hearts were then transplanted and evaluated 
over the course of 6 hours. All recipients receiving cold stored hearts required continued support 
on cardiopulmonary bypass and had increased creatine kinase release. Recipients receiving 
machine perfused hearts were able to be removed from cardiopulmonary bypass and pre-load 





spectroscopy and cardiac MRI to evaluate heart function after transplantation. They found that 
DCD hearts preserved with machine perfusion had almost complete metabolic recovery and 
replenishment of energy stores. The hearts also displayed excellent contractility following 
resuscitation with machine perfusion [38,39]. This finding confirms that machine perfusion can 
restore the viability of DCD hearts. However, these studies also discovered that machine 
perfusion is associated with myocardial edema, even at low perfusion pressures [33,36]. 
Fortunately, the occurrence of edema resolved in many cases after reperfusion on the 
Langendorff system and did not result in ventricle impairment. Overall, these studies suggest that 
machine perfusion has the potential to preserve donor hearts for long intervals and resuscitate 
hearts that have been damaged by warm ischemia.  
 
2.1.4 Human clinical trials of organ transplantation with machine perfusion 
 
The wealth of information provided by animal models has elucidated the potential of 
extracorporeal machine perfusion to improve post-transplantation outcomes, especially in 
extended criteria donors. These results have spurred interest in implementing machine perfusion 
in humans, which has resulted in numerous clinical trials that aim to compare outcomes between 
cold stored and machine perfused organs. Several devices, most tailored to a specific organ, have 
been developed for this purpose. The most common commercial machine perfusion systems used 








Figure 1. Most commonly used organ preservation systems. A) The OCS™ LUNG device   B) The OCS™ 
HEART device C) The OrganOx metra® device for liver preservation D) The LifePort® Kidney Transporter 
 
Kidney transplantation. Machine perfusion is occasionally used clinically for kidneys harvested 
from extended criteria donors or DCD. A pivotal study by Moers et. al. was the first large scale 
international, multi-center randomized control trial (RCT) to compare hypothermic machine 
perfusion and cold storage of kidneys [41]. The study involved 672 recipients: half received 
machine perfused kidneys, and the other half received cold stored kidneys. Machine perfused 
kidneys were preserved on the LifePort® Kidney Transporter device with University of 
Wisconsin (UW) solution at 1-8ºC.  Machine perfused kidneys had a decreased risk of delayed 
graft function (DGF) and graft failure. The most striking result was an increase in 1-year and 3-
year graft survival in the machine perfused group (Fig. 2) [41,42]. A retrospective study 
analyzed outcomes of 63 human clinical studies that compared machine perfusion and cold 
















non-oxygenated machine perfusion with UW, although there is still no consensus on optimal 
oxygen and temperature settings during machine perfusion. Generally, machine perfused kidneys 
had extended hours of cold ischemia when compared to cold storage, yet saw decreased DGF 
rates in standard grafts and decreased primary non-function (PNF) rates in ECD grafts [43]. 
Although no statistical significance was reached, there was a strong trend towards decreased 
acute rejection in machine perfused kidneys [43]. A different approach found that there were no 
statistically significant differences between machine perfused and cold stored kidneys unless 
they were harvested from ECDs that were greater than 60 years old. A trend was also seen 
towards less dialysis time and lower short-term hospitalization costs in machine perfused kidneys 
[44].  
 
Liver transplantation. One of the first clinical trials to compare machine perfused and cold 
stored livers was published in 2010. The study involved 20 recipients of machine perfused livers 






matched with recipients of cold stored livers. The livers were hypothermically (4-6°C) perfused 
with an acellular perfusate. This study found trends towards decreased DGF, biliary 
complications, serum injury markers, and shorter hospital stays [45]. The same group followed a 
different cohort of patients, 18 in the machine perfusion group, and 15 in the cold storage group, 
to analyze the effect on IRI markers. Recipients of machine perfused livers displayed decreased 
levels of inflammatory cytokines (e.g. TNF-α, MIP-1α), HIF-1β (a hypoxia-induced marker), and 
adhesion molecules upon reperfusion [46]. These findings suggest that hypothermic machine 
perfusion can reduce proinflammatory cytokines, which often activate pathways related to IRI. A 
few studies involving normothermic perfusion used the OrganOx metra® device for liver 
preservation with promising outcomes. One study followed 20 recipients of machine perfused 
livers matched with control patients. 30 days post-transplant found decreased AST levels and a 
reduction in DGF, with 3 occurrences in the machine perfused group versus 9 in the control 
group, although this was not statistically significant [47]. An important finding is that 
normothermic perfusion requires the addition of an oxygen carrier to the perfusate to support 
higher metabolic function within the organ, whereas it is sufficient for the perfusate to be 
equilibrated with room air in hypothermic perfusion [30,45]. A more recent RCT study preserved 
220 livers on the OrganOx metra® device. The authors found 50% lower levels of graft injury 
despite a preservation time that was 54% longer when compared to cold storage [48].  
 
Heart transplantation. Instances of machine preservation in heart transplantation are fewer than 
with kidneys and livers. However, hypo- and normothermic perfusion systems have been 
developed for this purpose. Although hypothermic systems are not yet used clinically, the 





RCT followed 67 patients in the OCS group and 63 patients in the cold storage group. 30-day 
patient and graft survival were similar in both groups and there were no significant differences in  
rates of rejection, length of ICU stay or cardiac related severe adverse events, despite longer 
preservation times in the OCS group (Fig. 3) [49]. However, outcomes suggested some 
advantages of machine perfusion over cold storage, namely reduced cold ischemia time  
(Fig. 3), improved ECD/DCD outcomes, and expanding time for distant graft procurement [50]. 
A small-scale trial in Australia involved three patients that received DCD hearts preserved on the 
OCS system. The hearts were subjected to less than 30 minutes of warm ischemia and preserved 
for an average of 254 minutes. All recipients showed favorable lactate uptake and normal cardiac 
function within one week of transplantation. Follow up at different post-operative days (176, 91, 
and 77 for each respective patient) showed good recovery [51]. Despite the lack of a control 
group and small group size, this trial demonstrated that machine perfusion can allow successful 
transplantation of DCD hearts.  The overall trend within these few trials is that machine 
Figure 3. Mean out-of-body preservation times for heart grafts. A) Mean total 





perfusion, despite no clear advantage over cold storage of the ideal donor graft, can improve 
quality of ECD donors and subsequently expand the donor pool.  
. 
Lung transplantation. Lung transplants are especially challenging procedures, not only because 
of the nature of the organ itself, but because over 80% of donor lugs are potentially injured and 
rejected by transplant teams [52]. Lungs are unique in that they need mechanical ventilation for 
optimal preservation. The OCS™ LUNG device was developed especially for this organ and has 
been used in several clinical trials. One study compared 20 high risk grafts (displaying 
pulmonary edema and poor deflation/inflation upon harvest) preserved on the OCS system with 
116 standard, cold-stored grafts. Despite poorer quality of grafts in the OCS group and nearly 
doubled preservation times (653min vs 370min), these lungs had a partial pressure arterial 
oxygen:fraction inspired oxygen ratios (PO2:FIO2) that were comparable to control lungs [52]. 
There were no significant differences in secondary outcomes or 1 year survival rates between the 
two groups [52]. This suggests that machine perfusion enables successful transplants of high risk 
donor lungs. Another trial utilizing the OCS™ LUNG device compared 308 standard cold-stored 
lungs with 14 lungs harvested from donors that had a higher percentage of smokers [53]. Despite 
the higher risk of these grafts, recipients had excellent survival rates and superior early outcomes 
and 3 and 6 months post-transplant [53]. A study involving DCD lungs yielded similar results 
upon comparison of transplant outcomes between OCS perfusion and cold storage [54]. The first 
prospective, multi-center RCT in machine perfusion for lung transplants was completed in 2018. 
151 patients received OCS perfused lungs and were compared with 169 cold-stored lung 
recipients [55]. The most compelling finding of this trial was a statistically significant decrease 





This suggests that machine perfusion can improve short-term outcomes following lung 
transplantation, but further studies would be needed to elucidate any long-term benefits. 
 
2.2 Vascularized Composite Allograft Perfusion 
 
Section 2.1 outlined the substantial success of solid organ transplantation and machine perfusion 
preservation. The improvement of surgical and preservation techniques ushered in by solid organ 
transplantation allowed VCA-Tx to become a possibility in the medical field. The potential of 
machine perfusion to improve solid organ preservation has sparked interest in applying this 
technology to VCAs.  
 
2.2.1 The emergence of vascularized composite allografts 
 
VCAs are transplanted as a functional unit that can correct defects that cannot be reconstructed 
with autologous tissues. As the name suggests, the feature that makes VCAs unique is the 
presence of different tissue types from the three germ layers [56]. This includes skin, muscle, 
tendon, nerve, bone and blood vessels. Other characteristics that distinguish VCAs from solid 
organ transplants include [56]: 
• Transplanted to enhance quality of life and are not life-saving  
• Are external, visible and are identifiable post-transplant 
• Require nerve regeneration to regain function 
The idea of extremity transplantations began to intrigue surgeons during World War II, but 
would not become a reality until many years later [57]. The applications of VCA-Tx can be 
clearly seen in military settings, where more than 1,500 American soldiers suffer traumatic limb 





second leading cause for extremity amputation [58]. The development of stronger 
immunosuppressant protocols in the 1990s led to successful transplant models in small and large 
animals [59]. Consequently, the first successful VCA-Tx was a hand transplant in 1998, and 
there have since been over 102 patients that have received upper extremity transplants world-
wide [57]. Facial transplants are also becoming more common, with the first procedure occurring 
in 2005 and increasing to over 30 recipients world-wide [57]. Other milestone procedures 
include the first transfemoral lower extremity in 2011, an abdominal wall transplant in 2003, a 
penile transplant in 2006, and a uterus transplant in 2000 [60]. 
 
2.2.2 Challenges in VCA preservation 
 
As with solid organ transplantation, the gold standard for VCA preservation is simple cold 
storage. However, VCA preservation is especially challenging because of the composite nature 
of the graft. Each tissue has different cold ischemic tolerance; for example, peripheral nerves and 
bone can tolerate up to 24 hours without detriment, while skeletal muscle and adipose tissue can 
deteriorate in as little as four [61,62]. Muscle is especially vulnerable to ischemic damage due to 
its high metabolic activity. Animal studies suggest that skeletal myocyte damage begins 3 hours 
post-ischemia and is often irreversible [63]. Due to this, it is likely that the muscle component 
will be the limiting factor in increasing preservation times. Establishing preservation time limits 
is further complicated by the variability of VCA and the nature of recipient defect, which causes 
procurement times to vary greatly—a facial allograft harvest could take well over 12 hours [64]. 
Although there is no established preservation time limit for VCAs, it is common to limit 
ischemia time to between 6-12 hours, after which risk of rejection may increase [64]. While 





is important to consider the unique needs of VCA. Individual tissues would have different 
metabolic demands, which would require development of a specialized perfusate. It is also 
important to note that the muscle component of VCA may be difficult to preserve on a machine 
perfusion system. Injury patterns in skeletal muscle components of VCA have shown a similarity 
to those seen in cardiac muscle, which is particularly susceptible to edema when subjected to 
machine perfusion, as discussed in section 2.1.4 [33,36,60].  
 
2.2.3 Animal models of VCA machine perfusion 
 
As VCA-Tx is still in its infancy, there are yet no clinical trials of machine perfusion with VCAs. 
The feasibility of applying this technique must first be verified in animal models before it can be 
translated into the clinical setting. An early study established the feasibility of ex-vivo perfusion 
of normothermic blood in porcine forelimbs. Limbs were either machine perfused or cold stored 
for 12 hours. It was found that muscle stimulation was possible throughout the perfusion 
preservation, whereas there was a lack of response in the cold ischemic control limbs, and 
histology suggested preservation of the graft [65]. Another porcine study used vertical rectus 
abdominis muscle flaps as VCA models. 8 flaps were preserved subnormothermically (21°) for 
14 hours, transplanted, and followed for 7 days. Compared to cold stored flaps, there was 
decreased IRI and post-transplant inflammation [66]. Figure 4 illustrates the remarkable 
difference between perfused and cold stored grafts at POD7. A porcine autotransplantation 
model used myocutaneous flaps preserved for 7 hours with normothermic perfusion in a 
hyperbaric, hyper-oxygenated chamber. The grafts were viable at POD21 with no signs of 
necrosis and outcomes comparable to cold stored grafts that were only preserved for 3 hours 





forelimbs that were preserved for 24 hours using normothermic machine perfusion with 
Figure 4. Representative images of machine perfused and cold stored VCAs at POD 0, 2, and 7. Cold stored 
grafts showed progressive signs of ischemic changes, including formation of ulcers around the nipples [65] 
Figure 5. Representative images of gracilis myocutaneous flap auto-transplants. 
Normothermic perfusion produced viable grafts on POD21. Outcomes are comparable 





autologous blood [67]. These limbs maintained neuromuscular electrical stimulation response, 
while cold stored limbs did not; single fiber muscle contractility was not significantly different in  
perfused limbs when compared to control contralateral limbs [67]. A recent study investigated 
the utility of subnormothermic oxygenated machine perfusion in a rat hindlimb transplantation 
model. Preliminary results showed that oxygen consumption was stable throughout the 2 hour 
preservation period along with decreasing lactate levels, which suggests restoration of metabolic 
activity [68]. All these studies strongly suggest that machine perfusion can extend the 
preservation time of VCAs past 4 hours with positive outcomes. Although more studies are 
needed to elucidate long-term effects of machine perfusion on VCA outcomes, the previously 
described results are encouraging.    
 
2.3 Development of Synthetic Perfusate Solutions 
 
2.3.1 Perfusate composition 
 
Arguably, the most crucial component of successful ex-vivo machine perfusion is the 
composition of the perfusate that circulates through the tissue. An ideal synthetic solution would 
replace the function of blood. This endeavor has been the subject of many research efforts since 
the emergence of machine perfusion more than 100 years ago. Belzer and Collins solutions were 
among the first to be produced and made cold storage techniques possible. Many subsequent 
solutions were made with either Belzer or Collins as the base with additional components to 
meet certain needs, such as oxygenation. As seen in Table 1, the composition of preservation 







Table 1. Compositions of perfusates commonly used for organ preservation 
Perfusate Solution Compositions 




























































L-Aspartic Acid Adenosine (5mM) 
Calcium chloride 
(0.5mM) 




L-Glutamic Acid Allopurinol (1mM) Ribose (5mM) Glucose (5mM) 























L-Leucine  Pentastarch (50g)  Glutamate (300mM)    
L-Methionine  a-ketoglutarate  Glutamine (400mM)    
L-Phenylalanine  L-arginine  Aspartate (20uM)    
L-Proline  N-acetylcysteine  Carnitine (50uM)    
L-Serine  Nitroglycerin  Choline (10uM)    




   
L-Tryptophan    
Human insuline 
(28mIU/L) 
   
L-Tyrosine        
L-Valine        
Lysine Acetate        





preservation solutions. In fact, a preclinical study with porcine kidneys showed conflicting 
results when different solutions were used for preservation [69]. Modifications to existing 
solutions are common, although establishing their efficacy is a matter of trail-and-error. 
However, the common goal of all solutions is to extend preservation times, and one of the main 
ways of doing this is to mitigate damage caused by hypoxic conditions and accompanying ATP 
depletion. Collins solution aims to preserve intracellular space composition upon ischemia. A 
high potassium content and glucose-based osmotic barrier was thought to achieve this but proved 
unsuccessful. The use of mannitol in place of glucose improved protection against prolonged 
ischemia. UW prevents edema with raffinose and lactobionate, mitigates ATP depletion by 
supplementing with a precursor of ATP (adenosine), and provides antioxidant properties with 
allopurinol. Histidine-tryptophan-ketoglutarate (HTK) contains histidine, a strong buffer, and 
mannitol, an osmotic barrier. Tryptophan and ketoglutarate are amino acids that help stabilize 
cell membranes. It is comparable to UW but has lower preservation costs [7].  
2.3.2 Perfusate additions for improved graft function 
 
Perfusion offers the unique opportunity of delivering therapeutic agents to VCAs prior to 
transplantation. This allows for the delivery of predetermined doses of therapeutic agents directly 
to the organ or graft and allow for subsequent monitoring This is especially important when 
optimizing tissues from extended criteria donors. Components can be added to the perfusate to 
maintain cellular integrity and vascular processes throughout the preservation time. Early 
attempts to do this yielded an acellular solution with a perfluorocarbon (PFC) emulsion. PFCs 
are inert solutions that have a great capacity for dissolving oxygen. A more recent addition is 
Hemarina-M101, an extracellular hemoglobin derived from marine invertebrates. It has a high 





Altering perfusion conditions could enhance expression of protective proteins. The heme analog 
cobalt protoporphyrin upregulates protective genes that can reduce free radical injury and have 
anti-inflammatory effects. Carbon monoxide is another example; it is a potent vasodilator that 
can promote flow and oxygenation during perfusion [22]. Cell-based gene therapies and stem 
cells could also be applied to perfusion techniques, which could achieve immunomodulation to 
reduce rejection or enhance tissue functionality [62]. Preliminary studies have shown that 
allografts can be transduced with CTLA4-Ig, a costimulatory blocker, to promote graft survival 
in a variety of tissue types [62]. Perfusing allografts with a solution containing an adenovirus to 
increase expression of an anti-oxidative enzyme in endothelial cells was shown to mitigate 
transplant related vasculopathy [62]. Another study aimed to alter the physiologic properties of 
allografts to imbue it with therapeutic properties. A mouse adipose graft was perfused with 
adenoviral vectors containing anti-tumor cytokines or anti-microbial peptides. After perfusion, 
the graft was inset over a recipient with exogenously delivered tumor or bacterial cells. They 
found reduced tumor growth and bacterial cell counts. Additionally, the authors found minimal 
systemic adenoviral dissemination and associated toxicity [62]. Another application involves 
delivery of stem cells, such as mesenchymal stem cells, to the graft which could potentially 
support survival via immunomodulation. It is clear that the importance of the perfusate and its 
components cannot be understated. A perfusate developed for the specific needs of an organ or 
graft can improve post-transplant outcomes and function, which is imperative for patient survival 







2.4 Muscle Electrical Stimulation  
 
2.4.1 Implementation and possible benefits 
 
Electrical stimulation has mainly been studied as a method to prevent atrophy of denervated 
muscle by tapping into the plasticity of the nervous system. Approaches such as neuromuscular 
electrical stimulation (NMES) involve stimulating nerves to induce functional movement of 
associated muscles [70]. This therapy can improve muscle strength and improve recovery rates in 
patients suffering from spinal cord injuries and has been shown to be beneficial in human 
subjects [70,71]. This method has also been useful in preserving different muscle groups in 
critically ill patients with little to no mobility [72,73]. It has also been suggested that electrical 
stimulation can reduce capillary regression and muscle loss in denervated rat hindlimbs [74]. 
Most of these protocols involve specialized circuit designs, including H-bridges with biphasic 
stimulus capabilities, and implantable stimulation electrodes. Modifications can be made to 
stimulate muscles remotely and minimize invasiveness of the procedure. Although the use of 
electrical muscle stimulation has not been applied to VCA preservation, plenty of evidence 
suggests that stimulation of the muscle could result in better functional post-transplant outcomes. 
The addition of this therapy to VCA preservation has the potential of maintaining the volume of 
the muscle component during extended preservation times. Electrical stimulation would provide 









3. Experimental Methods and Materials 
 
3.1 Abdominal Wall Recovery and Transplantation Procedures 
 
The murine abdominal wall transplant model is based on a procedure previously described by 
Broyles et. al [75].. Adult Lewis rats were housed with rat chow and water ad libitum, and 
maintained in accordance with institutional animal care and use committee guidelines. An 
illustrated representation of the complete procedure can be found in Appendix A.    
Abdominal wall recovery. Rats were placed in an induction chamber with 2.5% isoflurane. Once 
the animal was anesthetized, it was placed on a surgical board in the supine position with 
isoflurane delivered at 2-2.5% through a nose cone. Depth of anesthesia was evaluated by 
employing the toe-pinch reflex test. The reflex had to be absent before proceeding. Respiration 
was also monitored regularly and ensured to be regular with thoracic and abdominal components. 
The abdominal area was shaved and disinfected with alternating applications of betadine and 
70% alcohol. An area of the abdomen of approximately 4x4 cm was marked on either side of the 
linea alba. An incision was made at the inguinal canal and underlying fascia and fat were 
dissected to access the femoral and superficial epigastric vessels. Once these vessels were 
identified, the skin was incised around the previously determined perimeter. The first incision of 
the abdominal muscle was made at the linea alba. Bipolar cautery forceps were used to cauterize 
and cut the perimeter of the abdominal wall flap. The flap was then everted caudally, and internal 
organs were retracted to have a clear visual field. The external iliac vessels were identified and 
dissected from the bifurcation of the common iliac to just distal of the origin of the superficial 
epigastric vessels. All arterial and venous branches along the length of the main vessels were 





divided at their origin. The abdominal flap was then flushed with 10mL heparinized saline (HSa) 
to remove blood and cool the flap to room temperature. Depending on the experimental group, 
the flap was either transplanted, after approximately 1 hour of ischemia time, or connected to the 
machine perfusion circuit for preservation experiments. Prior to transplantation, the proximal 
ends of the external iliac vessels were prepared for suture-free vascular anastomosis using a cuff 
technique. The vessels were pulled through 22-gauge polyethylene cuffs, the ends everted over 
them and tied circumferentially with 10-0 silk sutures.  
Abdominal wall transplantation. Recipient animals were prepared in a similar fashion as the 
donors. The graft size was outlined on the abdomen and an incision made in the inguinal canal to 
expose the femoral vessels. The vessels were dissected, and any branches cauterized. They were 
then occluded with vessels clamps at their origin near the inguinal ligament. To preserve as much 
vessel length as possible, the femoral vessels were ligated and divided proximal to the origin of 
the superficial epigastric vessels. The vessels were irrigated with HSa. Vascular anastomoses 
were initiated by approximating the ends of donor external iliac vessels and recipient femoral 
vessels with a micro-vessel Acland clamp. The recipient’s vessels were pulled over the cuffs on 
the donor vessels and secured with circumferential ties. The vessel clamps were then removed, 
and blood flow was reestablished. Only a few minutes were necessary to visually observe the 
reperfusion of the grafts and a return to normal color. The graft was then carefully placed over 
the recipient’s abdomen to ensure the correct size and placement of incisions. Once this was 
established, the recipient skin and abdominal wall was removed. The donor graft was inset into 
the recipient; muscle and skin were subsequently sutured with 4-0 absorbable Vicryl.  
Post-operative care. Immediately after skin closure, the animals were given Baytril (10mg/kg) 





the surgical site. The animals were placed in their cage under a heating lamp until fully 
recovered from the anesthesia. Rats had to be active and mobile before being returned to the 
animal facility. Bandages were changed every two days and removed on POD7. Grafts were 
inspected and photographed regularly.  
 
3.2 Machine Perfusion and Settings 
 
The first preliminary experiments served to establish a basic perfusion system to determine if it 
could successfully perfuse the vasculature and to evaluate the effects of perfusion on the 
abdominal wall graft. The pump that was utilized was the Ismatec 8-channel peristaltic pump 
that provided continuous flow. After a graft was harvested and blood removed, a flushing needle 
connected to the tubing of the pump was inserted a few millimeters into the artery and secured 
with a silk tie. A small catheter was inserted into the vein to promote an open vessel and allow 
outflow. Perfusates were prepared as necessary for each experiment and are as follows: (i) HSa: 
40mL lactated ringers + 1mL (1,000USP) heparin (ii) HTK with no additions (iii) HTK-albumin: 
50mL + 6.25g bovine serum albumin (12.5% albumin). The perfusate was then placed in a 
reservoir that the pump would draw from. The perfusate would circulate through the graft and 
any outflow would return to the reservoir. Figure 6 shows the basic components required for this 
simple configuration. Perfusion experiments were conducted for 12 hours, after which the tissue 
was processed for analysis.  
 
The settings of the Ismatec pump allowed for a fixed flow rate or rotations per minute (RPM).  
Several variables were explored in an attempt to find optimal settings that would allow 





the perfusion system; one of the final prototypes is shown in Figure 7 with several in-line 
perfusate sensors, a force sensor, and electrical stimulation capabilities. Additions to the 
perfusion system, such as a bubble trap, oxygenation, and perfusate heating, are being explored 
but were not implemented at the time of these experiments.  
 
Table 2. Different variables tested for machine perfusion 
Variables 
Perfusate Flow Rate Perfusion Type 
HSa 0.5mL/min Continuous 
HTK 0.1mL/min Intermittent 
HTK-albumin   
 
Figure 6. Simple machine perfusion set up. The peristaltic pump 
draws perfusate from the reservoir and circulates it through the 








3.3 Realization of Bioreactor Housing 
 
When tackling the task of designing the bioreactor housing, it was important to consider the 
specific needs of the abdominal graft and the transplantation model. The bioreactor housing had 
to be designed to meet certain criteria, summarized as follows: 
• Allow for sterile assembly 
• Provide sterile, closed environment for graft perfusion 
• Maintain humidity within the chamber to promote graft hydration  
• Provide physiological stimulation to maintain muscle function 
Figure 7. One of the final bioreactor prototypes with necessary components. A) 
Complete perfusion system. From left to right: tubing from perfusion pump with 
in-line sensors leading into the bioreactor chamber, data acquisition system, 
bioreactor chamber. electrical stimulation system B) Front view of bioreactor 






• Secure graft during perfusion to minimize movement and enable acquisition of force 
measurements 
• Include ports to allow perfusate and external stimuli to be delivered to the graft 
To meet these criteria, the design had to include ports to allow access from the outside, clamps to 
secure the tissue in place, and a component to fix a force sensor. SolidWorks, a computer-aided 
design (CAD) program, was used to produce prototype models that could be 3D printed and 
tested before a design was finalized. Prototype printing was carried out on the LulzBot TAZ 5 
with PolyLite™ polylactic acid (PLA), which warps and shrinks less than other materials. 
Multiple iterations of prototypes were created. Modifications were made often, as each use of a 
prototype would elucidate any shortcomings and improvements that could be implemented.  
 
3.4 Electrical Stimulation Circuit 
 
The electric circuit had to be designed in a way that could stimulate the entire graft at once. To 
meet this goal, an H-bridge circuit was constructed. This electronic circuit enables a voltage to 
be applied across a load, which, in this case, is the abdominal wall graft. Figure 8 shows the 
circuit diagram of the H-bridge circuit used in these experiments. The components necessary to 
implement this circuit are illustrated in Figure 9. The H-bridge is unique in that it has two 
different current inputs and channel MOSFETs. Depending on the type of channel MOSFET, 
applied voltage will open or close a certain pathway. As voltage is applied to either Input A or B, 
they open and close rapidly, and the direction of current flow through the graft alternates (See 
Fig. 7). This produces biphasic stimulation with alternating current. This is important because 
monophasic stimulation results in a net ion flow within the tissue which causes ion gradient 





concept and ensure the H-bridge circuit could induce contractions. Voltage was applied between 
5-7V. As seen in Figure 9, tin-coated 22-gauge copper wires act as electrodes that can be placed 
on the graft to conduct current. The electrodes were placed on either side of the vascular tree, as 
shown in Figure 10. The tissue was stimulated at 70Hz with 300ms pulse trains every 5 seconds. 
Several methods were attempted to determine the most vigorous contractile response. Electrodes 
were placed on the surface of (i) a dry graft (ii) a graft moistened with lactated ringers (iii) a 
graft fully submerged in lactated ringers or (iv) a graft covered in SignaGel electrode gel. Videos 
were taken of these experiments and analyzed with a MatLab script to calculate the percentage 
contraction. After many trials, it was found that applying electrode gel produced the best 
contractile response with these electrodes and had the added benefit of maintaining graft 
hydration. Additional experiments were conducted after the graft was connected to the 
bioreactor’s perfusion system. Contraction force in this setting was measured by attaching a 
small wire into the medial or lateral side of the graft, depending on desired orientation, and 
attaching the other end to a force sensor, as illustrated in Figure 11 (ADInstruments 
MLT1030/D Wide Range Force Transducer). When the graft contracts, a force is applied to the 
sensor via the wire. The force sensor contains a strain gauge that changes electrical resistance 
when force is applied. This change can be measured and recorded with a data acquisition system 







Figure 8. H-Bridge circuit diagram. The circuit consists of two inputs, several resistors, P/N channel 
MOSFETS, and a voltage source. The resistor labeled “Load” represents the abdominal wall graft. Current is 
supplied by the voltage source (Vcc). When voltage is applied to Input A, current flows through the path 
highlighted in yellow. When voltage is applied to Input B, current flows through the path highlighted in blue. 
They grey area shows overlap where the current stimulates the graft. White arrows indicate direction of 
current 
 
Figure 9. Necessary components for electrical 
stimulation. A) Laptop B) Arduino 
microcontroller C) Power supply D) H-bridge 
circuit built on breadboard E) Platinum 
electrodes conducting voltage to graft 
Figure 10. Electrode placement on graft 






3.5 Implementation and Production of Metabolite Sensors 
 
A variety of sensors were procured or developed to measure different components in the 
perfusate. These could be important markers of viability and can provide feedback on the 
metabolic state of the graft throughout the preservation period. In-line sensors were utilized for 
non-invasive monitoring and were designed for placement in line with the tubing delivering 
perfusate to the graft. Sensors readily available on the market were procured for oxygen, pH, 
temperature, and pressure. Other sensors had to be developed for measurement of specific 
metabolites at low concentrations, including nitric oxide (NO), and hydrogen peroxide (H2O2). 
Figure 11. Connection of abdominal wall graft to force sensor. As the 
graft contracts, the force is conveyed to the force sensor through the 






Each sensor was placed both in in-flow and out-flow lines to monitor the graft's response to the 
circulating perfusate. Each sensor had to be calibrated before every experiment. Table 3 shows 
physiologic ranges of different parameters in rats that could be used to evaluate graft status. 
Table 3, Physiologic ranges of rat parameters 
Parameter Range/Mean Source 
Temperature (°C) 35.9 – 39.4 [76] 
pH 7.33 ± 0.07 [77] 
Pressure (mmHg) 91 - 129 [78] 
P_O2 (mmHg) 95.14 ± 14.42 [77] 
Lactate (mM) 1.09 ± 0.28 [79] 
Glucose (mg/dL) 60 - 125 [80] 
 
In-line sensors that had to be specially manufactured were produced by the Bioelectronics 
Laboratory at the University of Maryland, Baltimore County (UMBC). The H2O2 sensor was 
manufactured with a tungsten wire coated with a gold sheet. In order to increase sensitivity, the 
sheet was etched with concentrated nitric acid to produce a porous gold surface. The pores 
increased the surface area, which allowed increased functionalization. The surface was modified 
by adding 3-Mercaptoproionic acid (MPA), which has a sulfur (thiol) group and a carboxylic 
acid tail. The thiol groups bond strongly with gold atoms, and the carboxylic acid can be further 
functionalized. The next step involved conjugating horseradish peroxidase (HRP) to the reactive 
carboxylic acid tails. HRP catalyzes the reaction that reduces H2O2 into water and an electron. 
This released electron produces a current that can be detected, measured, and correlated with 
H2O2 concentration. Figure 12 summarizes this process. To evaluate the electrode, sensitivity, 
specificity and stability was determined, and calibration curves were produced. Sensitivity and 
specificity can be determined by subjecting the electrode to a neutral buffer like PBS and adding 
known concentrations of H2O2, as well as other molecules such as glucose and acetaminophen. 





occurring with other components in the perfusate. Calibration curves are constructed by 
evaluating the chronoamperometric response of the electrode. This is done by stepping the 
potential of the electrode by adding specific volumes of H2O2 in known concentrations in PBS. 
The resulting current can be monitored as a function of time, and a line of best fit can be 
extrapolated and used to find H2O2 concentration as a function of current.   
 
Figure 12. Production of sensing mechanism for H2O2 sensor. Figure provided courtesy of the Bioelectronics 
Laboratory at (UMBC) 
 
3.6 Tissue Analysis 
 
Samples were taken of the muscle component of the graft after each perfusion experiment to 
evaluate viability. The tissue was divided into 6 sections, as shown in Figure 13. Each section 
was snap-frozen in isopentane, cryo-sectioned, and stained with hematoxylin and eosin (H&E). 
Necrosis scores were assigned from 1-4 based on the following criteria: (1) non-homogenous 
eosinophilic staining (2) vacuole formation (3) hypercontraction (4) macrophage infiltration. 
Muscle fiber separation was determined as a measure of necrosis. Separation occurs due to 
rupturing of epimysium and endomysium. It can also indicate pressure-induced damage due to 
perfusion. Muscle separation was quantified by converting H&E images into binary, black and 





white areas to black areas. Grafts were weighed before and after perfusion to determine weight 
gain, which indicate extent of edema.   
 4. Results 
 
It is important to note that the results reviewed in this section reflect the progress made in the 
preliminary phases of the project. Progress is continuing as each component of the bioreactor is 
tested and optimized. 
 
Abdominal Wall Transplant 
The procedures conducted during this phase of the project were syngeneic transplants in order to 
optimize the procedure without the complications of immunosuppressive protocols and possible 
rejection episodes. Modifications were made to the surgical procedure outlined by Broyles et. al 
to adapt the transplantation model to the needs of this project. Namely, the graft size was reduced 
to approximately 3x3cm to maximize perfusion as several previous transplantation attempts 
found better success with smaller graft sizes. However, trials with securing the graft in the 






bioreactor found that a larger graft size would facilitate the process. The graft was harvested at a 
larger size so there would be extra tissue to secure clamps and electrodes. Tissue in contact with  
these elements may sustain damage, so a larger graft size would enable the removal of damaged 
tissue prior to transplant. This was found to be a feasible course of action by reducing graft size 
after harvest and immediately before transplant. Although no perfusion time was used in these 
trials, it was found that reducing graft size after harvest could yield successful transplantations. 
Figure 14 shows three successful syngeneic graft recipients on various PODs.  
 
Machine Perfusion Protocols 
Initial perfusion experiments involved perfusing methylene blue at 0.5mL/min to ensure that the 
perfusion system could access the vasculature of the graft. It was seen that the entire graft could  
be perfused in less than 20 minutes. This is illustrated in Appendix B. Subsequent experiments 
used HSa as the perfusate at 0.5mL/min for 12 hours at room temperature. This group was 
compared with two other groups: storage in HSa at room temperature (RT-static) or at 4°C (CS-
static) for 12 hours. Necrosis scores were lowest in the CS-static group, and highest in the 
perfusion group. Muscle fiber separation was the most severe in the perfusion group, and the 
Figure 14. Three recipients with successful syngeneic abdominal wall transplants. A) 





grafts experienced an average of 90% weight gain, compared with 30% in RT-static group and 
15% in CS-static. Figure 15 shows representative H&E slides of each group compared with a  
. 
fresh muscle sample. The disruption of cellular structure is evident in all experimental groups.  
Figure 16 shows the calculation of muscle fiber separation; it is clear to see increased white 
areas in the perfused sample. Figure 17 is a graphic representation of necrosis scores and fiber  
separation in each section of the abdominal muscle graft.  
 
 
Figure 16. Illustration of how muscle fiber separation is determined. The white area is representative of 
separation and can be quantified with a computer script. It is clear that the perfused sample has increased 
white areas, and therefore, increased muscle fiber separation.  
Figure 15.  Representative H&E staining of initial perfusion studies with HSa. Loss of cellular structures is 






Figure 17. Necrosis scores and degree of muscle fiber separation in perfused and static grafts. The general 
trend points to room temperature perfusion causing increased necrosis and fiber separation/swelling   
 
In an attempt to reduce swelling, the cauterized edges of the graft were removed to promote 
more perfusate outflow. The perfusate was also changed to HTK, a common organ preservation 
solution more suited to maintain balanced cellular components. Implementing these changes 
decreased swelling and necrosis scores, with an average of 50% weight gain. Figure 18 
illustrates these findings.  
  
Figure 18. Necrosis scores and degree of muscle fiber separation in grafts perfused with HTK and cauterized 





 To further reduce swelling, an intermittent pattern of perfusion was tested. Instead of 12 hours 
of continuous perfusion of HTK, the flap was perfused in 20-minute intervals for the first 8 
hours, then continuously perfused for the last four. Figure 19 shows the results of this perfusion 
pattern. It provided further reduction in pressure induced injury, although necrosis. scores 
remained unchanged. Additional experiments were carried out by adding 12.5% bovine serum 
albumin to the HTK solution. Adding this protein to the perfusate increased the oncotic pressure 
and promoted fluid retention, therefore reducing tissue edema. Weight gain decreased from 
previous experiments and was approximately 30%. Flow rate was also reduced to 0.1mL/min to 
further reduce pressure-induced damage. Figure 20 shows histology of muscle tissue subjected 
to different perfusion protocols with HTK. It is evident that these protocols reduced edema and 
muscle separation, but muscle viability was greatly compromised in all experimental samples, 
with vacuole formation visible in every image. This suggests a need for improved perfusate 
composition.   
Figure 19. Necrosis scores and degree of muscle fiber separation in intermittent and continuous perfusion 
with HTK. Fiber separation was reduced, indicating reduced pressure-induced injury and swelling. Necrosis 






Prototype models were constructed using SoldWorks software. The main components included 
in every iteration were: (i) electrode connection tabs for electrical stimulation (ii) tissue 
mounting plate (iii) tissue clamps (iv) force sensor and (v) perfusion ports. Figure 21 shows a 
top-down view of the initial prototype with all these components are labeled. Figure 22 shows 
these components in greater detail. The metal tabs allow attachment of alligator clips that allow 
conduction of electrical stimulations from the external H-bridge to the graft inside the closed 
bioreactor. The tissue clamps secure the tissue and minimize movement, as well as providing a 
counter force for the force sensor to acquire data upon contraction. The small slits on the 
mounting plate allow perfusate to collect in a reservoir underneath the platform, where it can be 
taken up by the pump for recirculation. For ease of assembly, the bioreactor was constructed 
with removable sides and roof. This allows the rest of the construct to be permanently 
Figure 20. Representative H&E slides of muscle tissue subjected to different perfusion protocols. HTK 
reduces swelling and pressure-induced damage when compared with HSa, but necrosis scores remained 






assembled, and the only steps necessary to complete a closed environment are to slide the walls 
into place (Fig. 23).  
Figure 22. Close-up views of bioreactor components. A) Broad view showing force sensor (yellow), electrical 
stimulation tabs, and tissue mounting plate B) Tissue mounting plate and tissue clamps C) Tissue clamps and 
where force sensor connects with the tissue 
 
Figure 21. Top-down view of bioreactor SolidWorks model. The necessary components for perfusion and 





Every individual component, including removable walls, was printed on the LulzBot TAZ 5 and 
fully assembled before use. Figure 24 shows the bioreactor prototype after 3D printing and 
assembly, and how the graft can be placed on the tissue mounting plate and connected to the 
perfusion ports.  
 
 
Figure 23. Modification of bioreactor prototype for ease of assembly. Sides are roof are 






It was found that applying SignaGel to the surface of the graft was the most effective in inducing 
a vigorous muscular contraction. Figure 25 shows placement of electrodes on gel-coated tissue, 
and the graft before and after contraction.  
Figure 24. Assembled prototype and connection to abdominal wall graft. A) 
Perfusion system with peristaltic pump (left) delivery perfusate through tubing to 
bioreactor (right) B) Outside view of bioreactor chamber C) Inside view of chamber 
with perfusion needle attached to artery 
Figure 25. Electrical stimulation induces muscular contraction. A) Muscle at rest, before 






Fatigue tests showed that both 5-second and 2-minute intervals between applied stimulation 
fatigued the muscle before six hours post-surgery (Fig. 26). With 5 second intervals, the percent 
contraction (change in graft length) was lower than with 2-minute intervals, and contractions 
ceased at an earlier time point. Although electrical stimulation of the muscle was achieved, no 
force measurements were acquired. The force sensor needs further calibration and the bioreactor 
chamber needs further modifications to better enable force measurements. 
 
Figure 26. Fatigue test for 2-minute and 5-second intervals in electrical stimulation. Response to stimulation 
gradually reduced until no contraction was observed.  
 
Metabolite Sensors 
The Tungsten-wire based H2O2 electrode was found to have a linear dynamic range of 800pM to 
5mM, which is wide enough to detect the physiologic ranges found in most organisms, including 









concentrations. Responses were within 3 seconds, indicating an electrode with fast response 
behavior. Figure 28 shows the calibration curves extrapolated from these responses. 
 
 
Figure 27. Chronoamperometric response of H2O2 electrode at different concentrations. A) Responses to 
5nM (a), 500nM (b), 5uM (c) of H2O2. B) Response to 1mM (d) H2O2. This shows fast response behavior and 
allows for subsequent calibration curves. Figure provided courtesy of the Bioelectronics Laboratory at 
UMBC 
Figure 28. Steady-state current-time responses of Tungsten electrode to different 
H2O2 concentrations. This yields a wide linear range of sensitivity from 800uM to 





The reduction currents of H2O2 were linear in the range of 800pM to 5mM, with a correlation 
coefficient of 0.99. This linear range covers the physiological concentrations known for H2O2. 
The specificity of the sensor was determined by adding interfering species to the buffer. Current 
was only increased with the addition of H2O2, and none of the other species (Fig. 29). 
Other sensors that were employed were able to detect pressure, temperature, and percent oxygen 
in in-flow and out-flow perfusate. Figure 30 shows examples of the data acquired by these 
sensors.  
Figure 29. Selectivity of H2O2 Tungsten electrode. Additions of 
glucose, uric acid, ascorbic acid, and acetaminophen do not induce a 
change in current. This shows that the electrode is sensitive to H2O2 
only. Figure provided courtesy of the Bioelectronics Laboratory at 







Figure 30. Sample data acquired from in-line sensors during perfusion experiments. A) Pressure readings B) 
Temperature reading; blue indicates inflow; orange indicates outflow C) Oxygen content readings; blue 









The murine abdominal wall transplant model was established as successful, technically feasible, 
and reproducible in our lab. Daily monitoring is important to observe any mechanical trauma 
caused by auto-mutilation, and to take appropriate steps to prevent further trauma to the graft. 
Additional transplants must be completed in order to monitor graft survival and animal behavior 
past POD10.  
Bioreactor prototypes can be effectively produced using SolidWorks models and 3D printing 
techniques. Each component can be individually printed and assembled prior to use. Changes in 
the structure can be made to existing SolidWorks models to improve iterations of the prototype. 
The latest prototype is built for ease of assembly. Further prototypes will include spring-loaded 
clamps for simpler securing of the tissue, rubber sealing to ensure a closed environment for 
optimal humidity and sterility, and the implementation of an arterial catheter to reduce potential 
damage to the artery.  
The perfusion system can be set up with in line sensors for pH, oxygen, temperature, and 
pressure. Calibration of each sensor prior to each experiment ensures more consistent data 
throughout. Each sensor in the in-flow and out-flow pathways can provide real-time data through 
the data acquisition system. The rate of the perfusion pump can be fixed in order to control 
pressure throughout the perfusion. Rates of both 0.5mL/min and 0.1mL/min are effective in 
perfusing the vasculature of the graft in a short amount of time, but pressures must be monitored, 
and rate can be adjusted to maintain pressure within a certain range. It was evident in early 
experiments that HSa perfusion caused more damage to the graft than static preservation, 
regardless of storage temperature. Although HTK reduced edema when compared to HSa, it was 





pressure and encourage fluid retention. This helped to reduce swelling to approximately 30%, so 
there is still room for improvement. Removing the cauterized edges of the graft also helped to 
relieve swelling, but this is not translatable to future transplantation procedures as un-cauterized 
edges would bleed freely following reestablishment of perfusion. There were not enough 
perfusion trials to reach statistical significance but observing general trends during the 
preliminary phase of this project allowed modifications in methods while reducing excessive use 
of resources. Future experiments require further additions to the perfusate, namely oxygen 
carriers, glucose, vasodilators, and antibiotics. These additions will allow for better maintenance 
of metabolism and graft viability. The sensors will be integral in determining optimal additions 
of each component.  
The electrical stimulation circuit was able to induce muscular contractions in the graft, although 
contraction force decreased over time. In an ideal environment, the muscle would be receiving 
enough nutrients to replenish energy stores and waste removal to prevent accumulation of toxic 
end-products. This scenario would, ideally, prevent or diminish muscle fatigue and allow 
muscular contractions to occur throughout the 12-hour preservation period. Unfortunately, the 
force sensor was unable to gather meaningful data, as it needs further calibration and additional 
modifications within the tissue mounting plate for proper function. Intervals at which stimulation 
should be applied must be determined, although our fatigue tests suggest intervals of greater than 
10 minutes to maintain more uniform contractions.  
The H2O2 sensors can reliably and effectively measure H2O2 concentrations, even in the 
presence of interfering species. However, this function was determined in a neutral buffer, so 
further experiments will require the use of the perfusate used in perfusion experiments. By 





the same in our experimental perfusate. Once this sensor is finalized, it will be able to measure 
H2O2 concentration and correlate it to presence of ROS to evaluate tissue damage and ischemia. 
Sensors will also need to be manufactured to detect nitric oxide and lactate, for further 
determination of tissue viability.  
In conclusion, our experiments have shown that our machine perfusion system can perfuse the 
vasculature of the murine abdominal wall graft, much in the same way as solid organ perfusion 
systems can. Although the basic principles behind solid organ machine perfusion can be applied 
to VCA perfusion, it is important to understand that the vasculature must be maintained in order 
to perfuse the different components of the graft. For example, different vessels may perfuse the 
skin and fat layers, while others perfuse the muscle. Constructing a custom bioreactor greatly 
facilitates the process of connecting the graft to the perfusion system, while also enabling 
electrical stimulation and perfusate monitoring. The perfusates used thus far, however, are 
insufficient to extend graft survival. However, as this project is in its very early phases, there is 
still much experimentation needed to determine the optimal conditions for successful 
preservation of the abdominal wall graft. This includes pressure settings, temperature settings, 
perfusate composition, and viability marker profiles. It is clear that the perfusate is one of the 
most important components that must be optimized for enhanced graft preservation. Future work 
is also needed to acquire contraction force data, as well as H2O2 data, in conjunction with 12-
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